Forte Biosciences (FBRX) Total Non-Current Liabilities (2016 - 2026)
Forte Biosciences' (FBRX) quarterly Total Non-Current Liabilities came in at $23.6 million in Q1 2026, up 13.96% on a QoQ basis from $20.8 million in Q4 2025.
Forte Biosciences (FBRX) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 5 years of Total Non-Current Liabilities data on file, last reported at $23.6 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $23.6 million in Q1 2026; TTM through Mar 2026 was $23.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $20.8 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $23.6 million, up from $20.8 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for FBRX reached as high as $23.6 million in Q1 2026 and fell as low as $20.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - | 23.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.65 Mn |
| Dec 31, 2025 | 20.75 Mn |
| Dec 31, 2019 | 17.23 Mn |
| Sep 30, 2019 | 50.87 Mn |
| Mar 31, 2017 | 35.74 Mn |
| Dec 31, 2016 | 28.23 Mn |